Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging.

Autor:	Krell-Roesch J; Translational Neuroscience and Aging Laboratory, Mayo Clinic, Scottsdale, AZ, USA.; Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany., Vassilaki M; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Mielke MM; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Kremers WK; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Lowe VJ; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Vemuri P; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Machulda MM; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA., Christianson TJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Syrjanen JA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Stokin GB; International Clinical Research Center/St. Anne Hospital, Brno, Czech Republic., Butler LM; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Traber M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Knopman DS; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Roberts RO; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Petersen RC; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Geda YE; Translational Neuroscience and Aging Laboratory, Mayo Clinic, Scottsdale, AZ, USA. geda.yonas@mayo.edu.; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. geda.yonas@mayo.edu.; Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA. geda.yonas@mayo.edu.; Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA. geda.yonas@mayo.edu.
Jazyk:	angličtina
Zdroj:	Translational psychiatry [Transl Psychiatry] 2019 Mar 28; Vol. 9 (1), pp. 123. Date of Electronic Publication: 2019 Mar 28.
DOI:	10.1038/s41398-019-0456-z
Abstrakt:	Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A-) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A- (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A-, 446 CU/A+, 78 MCI/A-, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A-. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer's disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu